No Result
View All Result
SUBMIT YOUR ARTICLES
  • Login
Wednesday, October 22, 2025
TheAdviserMagazine.com
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal
No Result
View All Result
TheAdviserMagazine.com
No Result
View All Result
Home Medicare

As Insurers Struggle With GLP-1 Drug Costs, Some Seek To Wean Patients Off

by TheAdviserMagazine
2 months ago
in Medicare
Reading Time: 5 mins read
A A
As Insurers Struggle With GLP-1 Drug Costs, Some Seek To Wean Patients Off
Share on FacebookShare on TwitterShare on LInkedIn


After losing 50 pounds on the injectable weight loss medication Zepbound, Kyra Wensley received a surprising letter from her pharmacy benefit manager in April.

Her request for coverage had been denied, the letter said, because she’d had a body mass index of less than 35 when she started Zepbound. The 25-year-old who lives in New York had been taking Zepbound without incident for months, so she was confused: Why was her BMI, which had been around 32 when she started, becoming an issue only now?

Wensley had no interest in quitting an effective drug. “Going right off like that, it’s easier said than done,” she said.

Kyra Wensley’s doctor fought to keep her on the injectable weight loss medication Zepbound, but Wensley ultimately had to switch to Wegovy, a different GLP-1 agonist, to meet her health plan’s requirements.(Lori Wensley)

Her doctor fought to keep her on the GLP-1 agonist, the category that includes weight loss and Type 2 diabetes drugs Ozempic, Wegovy, Mounjaro, and Zepbound. But Wensley ultimately had to switch from Zepbound to Wegovy to meet her plan’s requirements. She said she doesn’t like Wegovy as much as her old medication, but she now feels lucky to be on any GLP-1.

Lots of research suggests such medications must be used indefinitely to maintain weight loss and related health benefits. But with list prices of roughly $1,000 a month, public and private payers are struggling to keep up with ballooning demand for GLP-1 weight loss drugs and in some cases are eliminating or restricting their coverage as a result.

North Carolina Medicaid plans to end GLP-1 coverage for weight loss on Oct. 1, just over a year after starting the coverage. Pennsylvania is planning to limit Medicaid coverage to beneficiaries at the highest risk of complications from obesity. And despite recent reports of a potential federal pilot program to extend coverage of GLP-1 obesity drugs under Medicaid and Medicare, all state Medicaid programs are likely to be under pressure due to steep spending cuts in the budget reconciliation package recently signed into law by President Donald Trump.

Already, many GLP-1 users quit within a year, studies suggest — often due to side effects, high costs, or insurance issues. Now a growing number of researchers, payers, and providers are exploring deliberate “deprescription,” which aims to taper some patients off their medication after they have taken it for a certain amount of time or lost a certain amount of weight.

The U.K.’s National Institute for Health and Care Excellence, which creates guidance for the National Health Service, recommends two-year limits on the use of some weight loss medications, such as Wegovy. And the concept was raised in a recent Institute for Clinical and Economic Review report on affordable access to obesity drugs.

A. Mark Fendrick, who directs the Center for Value-Based Insurance Design at the University of Michigan, has argued that if some people using GLP-1s to lose weight were eventually transitioned off, more people could take advantage of them.

“If you’re going to spend $1 billion or $100 billion, you could either spend it on fewer people for a long period of time, or you can spend it on a lot more people for a shorter period of time,” he said.

Email Sign-Up

Subscribe to KFF Health News’ free Morning Briefing.

Fendrick’s employer, the University of Michigan, indeed does that. Its prescription drug plan caps coverage of GLP-1 drugs at two years if they’re used solely for weight loss.

Jamie Bennett, a spokesperson for Wegovy and Ozempic maker Novo Nordisk, declined to comment on the concept of deprescription, noting that its drugs are intended for chronic conditions. Rachel Sorvig, a spokesperson for Zepbound and Mounjaro manufacturer Eli Lilly, said in a statement that users should “talk to their health care provider about dosage and duration needs.”

Studies have shown that people typically regain a substantial amount of weight within a year of stopping GLP-1 medications, and that many people who quit ultimately go back on the drugs.

“There’s no standard of care or gold standard on how to wean right now,” said Allison Adams, an obesity and internal medicine doctor with UK HealthCare in Kentucky.

But the math shows why time-limited coverage is appealing to payers that struggle to pay for beneficiaries’ GLP-1 prescriptions, said Michelle Gourdine, chief medical officer for the pharmacy benefit manager CVS Caremark.

And states are “between a rock and a hard place,” said Kody Kinsley, who until January led North Carolina’s Health and Human Services Department. “They’re going to have to look at every single thing and trim dollars everywhere they can.”

Pennsylvania was looking for cost-saving strategies even before the new federal tax-and-spending law, according to Brandon Cwalina, press secretary for the state’s Department of Human Services. Pennsylvania projects it will spend $1.3 billion on GLP-1 drugs this year.

Plans could see real savings, Fendrick said, if they covered GLP-1s for initial weight loss then moved people to cheaper options — such as more affordable drugs or behavioral health programs — to maintain it.

Plenty of companies are eager to sell insurers, employers, and individuals on behavioral alternatives. One is Virta Health, which advertises its nutrition-focused weight management program as “a proven approach for deprescribing GLP-1s when clinically appropriate.” A Virta-funded study assessed 154 people with Type 2 diabetes who stopped using GLP-1 medications but continued following Virta’s program, concluding that their weight did not significantly increase after a year.

Researchers affiliated with a European weight management company also recently reported that slowly tapering off the medications may help maintain weight loss.

For employers and insurers, the “initial question” was whether to cover GLP-1s for obesity, said Virta CEO Sami Inkinen. “Now, basically, everyone’s coming to the middle and asking, ‘How do we responsibly cover these drugs?’”

Part of responsible coverage, Inkinen said, is providing other forms of support to patients who stop using GLP-1 medications, by choice or otherwise.

For some people, however, maintaining weight loss without a GLP-1 remains a challenge, even with other options available.

Lily, who lives in Michigan, lost almost 80 pounds in roughly 18 months on Wegovy. But she had to quit the drug when she turned 26 and left her parents’ insurance plan this year. The plan her employer offers stopped covering GLP-1s for weight loss right around the time she joined.

Lily, who asked to be identified by only her first name because she is not out to her family as transgender, has tried other medications since then, and previously tried lifestyle programs to control her weight. But she said nothing works as well for her as Wegovy.

She has regained 20 pounds since going off the drug at the beginning of the year and worries that number will continue to rise, potentially contributing to future health problems.

“Just give people the drugs,” she said. “It seems cheaper and safer in the long run.”

Related Topics

Contact Us

Submit a Story Tip



Source link

Tags: CostsdrugGLP1InsurerspatientsseekStruggleWean
ShareTweetShare
Previous Post

Football Players | Nonresident Income Tax Filing

Next Post

What if artificial intelligence is just a “normal” technology?

Related Posts

edit post
Private Medicare, Medicaid Plans Exaggerate In-Network Mental Health Options, Watchdogs Say

Private Medicare, Medicaid Plans Exaggerate In-Network Mental Health Options, Watchdogs Say

by TheAdviserMagazine
October 20, 2025
0

Tony Leys Companies running private Medicare and Medicaid insurance plans inaccurately list many mental health professionals as being available to...

edit post
States Jostle Over B Rural Health Fund as Trump’s Medicaid Cuts Trigger Scramble

States Jostle Over $50B Rural Health Fund as Trump’s Medicaid Cuts Trigger Scramble

by TheAdviserMagazine
October 17, 2025
0

Abe Sutton, director of the Centers for Medicare & Medicaid Services Innovation Center, speaks to state officials and corporate sponsors...

edit post
Guide to Medicare Open Enrollment

Guide to Medicare Open Enrollment

by TheAdviserMagazine
October 16, 2025
0

Fall is the time when many people choose what health care coverage they will have in the coming year, and...

edit post
Medicare Open Enrollment Begins Today

Medicare Open Enrollment Begins Today

by TheAdviserMagazine
October 15, 2025
0

Medicare Open Enrollment (also known as the Annual Election Period) begins today! From October 15 to December 7, you can...

edit post
In Mississippi, Medicaid Coverage of Weight Loss Drugs Fails To Catch On

In Mississippi, Medicaid Coverage of Weight Loss Drugs Fails To Catch On

by TheAdviserMagazine
October 15, 2025
0

COLUMBUS, Miss. — April Hines has battled with her weight since she was a teenager. But in the past couple...

edit post
How to Enroll in an Independence Blue Cross Health Insurance Plan

How to Enroll in an Independence Blue Cross Health Insurance Plan

by TheAdviserMagazine
October 14, 2025
0

We know health insurance can be complicated. That’s why we try to make it easy to find a health plan...

Next Post
edit post
What if artificial intelligence is just a “normal” technology?

What if artificial intelligence is just a “normal” technology?

edit post
Sam Altman Says Rise in Twitter Bots Lends Credence to Dead Internet Theory

Sam Altman Says Rise in Twitter Bots Lends Credence to Dead Internet Theory

  • Trending
  • Comments
  • Latest
edit post
77-year-old popular furniture retailer closes store locations

77-year-old popular furniture retailer closes store locations

October 18, 2025
edit post
Pennsylvania House of Representatives Rejects Update to Child Custody Laws

Pennsylvania House of Representatives Rejects Update to Child Custody Laws

October 7, 2025
edit post
What to Do When a Loved One Dies in North Carolina

What to Do When a Loved One Dies in North Carolina

October 8, 2025
edit post
Probate vs. Non-Probate Assets: What’s the Difference?

Probate vs. Non-Probate Assets: What’s the Difference?

October 17, 2025
edit post
California Attorney Pleads Guilty For Role In 2M Ponzi Scheme

California Attorney Pleads Guilty For Role In $912M Ponzi Scheme

October 15, 2025
edit post
Baby Boomers Are Flocking to This Florida Town — but Not for the Weather

Baby Boomers Are Flocking to This Florida Town — but Not for the Weather

October 9, 2025
edit post
Willow Processor Maps Molecules 13,000x Faster Than Supercomputer: Google

Willow Processor Maps Molecules 13,000x Faster Than Supercomputer: Google

0
edit post
15 Best-Paying States for Women in Construction

15 Best-Paying States for Women in Construction

0
edit post
Alleged loan fraud is frustrating but isolated

Alleged loan fraud is frustrating but isolated

0
edit post
Generation Capital raises NIS 280m on TASE

Generation Capital raises NIS 280m on TASE

0
edit post
Takeda Pharmaceutical Company (TAK) Signs a Research Partnership with Nabla Bio

Takeda Pharmaceutical Company (TAK) Signs a Research Partnership with Nabla Bio

0
edit post
Is the Internet Dead? – Banyan Hill Publishing

Is the Internet Dead? – Banyan Hill Publishing

0
edit post
Willow Processor Maps Molecules 13,000x Faster Than Supercomputer: Google

Willow Processor Maps Molecules 13,000x Faster Than Supercomputer: Google

October 22, 2025
edit post
Alleged loan fraud is frustrating but isolated

Alleged loan fraud is frustrating but isolated

October 22, 2025
edit post
Is the Internet Dead? – Banyan Hill Publishing

Is the Internet Dead? – Banyan Hill Publishing

October 22, 2025
edit post
LDI in Frontier Markets: Building Resilience, the Nigeria Case Study

LDI in Frontier Markets: Building Resilience, the Nigeria Case Study

October 22, 2025
edit post
Pegasystems signals accelerating Pega Cloud momentum with ACV growth and partner-driven AI innovation (NASDAQ:PEGA)

Pegasystems signals accelerating Pega Cloud momentum with ACV growth and partner-driven AI innovation (NASDAQ:PEGA)

October 22, 2025
edit post
15 Best-Paying States for Women in Construction

15 Best-Paying States for Women in Construction

October 22, 2025
The Adviser Magazine

The first and only national digital and print magazine that connects individuals, families, and businesses to Fee-Only financial advisers, accountants, attorneys and college guidance counselors.

CATEGORIES

  • 401k Plans
  • Business
  • College
  • Cryptocurrency
  • Economy
  • Estate Plans
  • Financial Planning
  • Investing
  • IRS & Taxes
  • Legal
  • Market Analysis
  • Markets
  • Medicare
  • Money
  • Personal Finance
  • Social Security
  • Startups
  • Stock Market
  • Trading

LATEST UPDATES

  • Willow Processor Maps Molecules 13,000x Faster Than Supercomputer: Google
  • Alleged loan fraud is frustrating but isolated
  • Is the Internet Dead? – Banyan Hill Publishing
  • Our Great Privacy Policy
  • Terms of Use, Legal Notices & Disclosures
  • Contact us
  • About Us

© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal

© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.